Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Oncologists who Treat Hematologic Malignancies (US)

Articles with lock require a subscription to GLG News | Request a free trial
May 7, 2008
Genomics are coming! Are we ready?
Analysis of: Cancer-Gene Test Boosts Myriad's Sales | online.wsj.com
Author: GLG Expert Contributor
Myriad Genetics Inc. went directly to the patients who then were tested whether the tests were indicated or paid for by insurers or out of their own pockets. If patients have "medical savings accts" as suggested by various political candidates, right or wrong patients will want it with this kind...
May 6, 2008
Curis, Inc (CRIS, NASDAQ) & Genentech in partnership Re: a hedgehog antagonist in colon cancer
Analysis of: Curis Announces Genentech's Initiation of Hedgehog Antagonist Phase II Clinical Trial In Metastatic Colorectal Cancer | www.pipelinereview.com
Author: GLG Expert Contributor
GDC-0449 is an oral agent that will be added to "standard" therapy in metastatic colorectal carcinoma (CRC) and evaluating progression free survival as the primary objective.
May 6, 2008
Amplimed (?) anything for pancreatic ca would be worthwile.
Analysis of: AmpliMed Corporation Announces Start of Randomized Phase 2 Trial of Amplimexon in Pancreatic Cancer | www.pipelinereview.com
Author: GLG Expert Contributor
An interesting randomized phase II trial of Gemzar (the current standard with Tarceva) vs imexon + Gemzar. BUT shouldn't it be compared to Gemzar/ Tarceva??
May 5, 2008
AstraZeneca's (AZ) IRESSA still alive in Europe.....? There is life after failure in the US.
Analysis of: AstraZeneca Files Marketing Application in Europe for EGFR Inhibitor Gefitinib (IRESSA(TM)) in Locally Advanced Pre-Treated Non-Small Cell Lung Cancer | www.pipelinereview.com
Author: GLG Expert Contributor
Approval will be base on the phase III INTEREST trial that showed in NSCLC that Iressa was "non-inferior" to standard chemotherapy after platinum therapy failure first line. Iressa was better tolerated and had an improved quality of life.
May 5, 2008
BITE antibodies for solid tumors: Still more bark than bite!!!
Analysis of: Micromet Enrolls First Patient in Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors | www.pipelinereview.com
Author: GLG Expert Contributor
Micromet's Bite antibodies strategy garners the patient's T-cells to attack tumor cells. This technology showed proof of principle i hematological malignancies , and now a Phase I clinical trial has commenced for solid tumors. The rationale is intriguing, but immunotherapy has been elusive in solid...
May 1, 2008
Genomics!!! I told you so......
Analysis of: New Study Ties Genes To Leukemia Treatment | online.wsj.com
Author: GLG Expert Contributor
Gene mutation analysis can help refine therapy in acute leukemia and impact on results!!
April 30, 2008
Rituxan ( Vitamin R ): Let's not panic!!
Analysis of: Wider Aim for Rituxan Fails | online.wsj.com
Author: GLG Expert Contributor
Rituxan failed to improve various parameters and targets in a rather comprehensive study of patients with Lupus.
April 28, 2008
More potential developments in chronic lymphatic leukemia (CLL) therapy!
Analysis of: IL-21 mediates apoptosis through up-regulation of the BH3 family member BIM and enhances both direct and antibody-dependent cellular cytotoxicity in primary chronic lymphocytic leukemia cells in vitro | bloodjournal.hematologylibrary.org
Author: GLG Expert Contributor
ZymoGenetic appears to have a biologic that will expedite lymphocytes apoptosis (destruction) when combined with Fludara and Rituxan- 2 standard agents in this rather common & occasional refractory condition.
April 28, 2008
A Non Epo Product for Anemia of Chemotherapy? Will this dog hunt?
Analysis of: Oral PBI-1402 Demonstrates Significant Activity in Chemeotherapy-Induced Anemia Phase II Clinical Trial | www.pipelinereview.com
Author: GLG Expert Contributor
This non erythropoietin (Epo) product will raise hemoglobin levels and decrease the need for transfusions.
April 24, 2008
Advance in Small Cell Lung Cancer (SCLC)?
Analysis of: Poniard reports positive results for lung cancer drug | www.cnbc.com
Author: GLG Expert Contributor
Doubles survival BUT "comparator" arm is best supportive care. See http://investor.poniard.com/ReleaseDetail.cfm?ReleaseID=306218

Previous Page : 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 Next81 to 90 of 727

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-08-30T05:45:15.877